Talzenna will be approved for the treatment of gBRCA advanced breast cancer in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Talzenna after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Talzenna will be observed.
Study Type
OBSERVATIONAL
Talzenna treatment under Korea regulatory approval indication/dosage
Incidence of adverse events categorized according to physical organ and disease/symptom
It is non-interventional, observational study in the real world setting. Adverse events will be captured in the real world clinical practice.
Time frame: From date of randomization until the 28 calendar days following the last administration of a drug under study
Overal response (Effectiveness outcome) by Response Evaluation Criteria In Solid Tumors (RECIST) critera
It is non-interventional, observational study in the real world setting. Response evaluation will be assessed based on the real world clinical practice
Time frame: through study completion, an expected average of 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.